Radiotherapy in the Treatment of Subcutaneous Melanoma.

Cancers (Basel)

Radiation Oncology Unit, Istituto Nazionale Tumori-IRCCS-Fondazione G. Pascale, 80131 Napoli, Italy.

Published: November 2021

Malignant melanoma frequently develops cutaneous and/or subcutaneous metastases during the course of the disease. These may present as non-nodal locoregional metastases (microsatellite, satellite, or in-transit) included in stage III or as distant metastases in stage IV. Their presentation is heterogeneous and associated with significant morbidity resulting from both disease-related functional damage and treatment side effects. The standard treatment is surgical excision, whereas local therapies or systemic therapies have a role when surgery is not indicated. Radiotherapy can be used in the local management of ITM, subcutaneous relapses, or distant metastases to provide symptom relief and prolong regional disease control. To increase the local response without increasing toxicity, the addition of hyperthermia and intralesional therapies to radiotherapy appear to be very promising. Boron neutron capture therapy, based on nuclear neutron capture and boron isotope fission reaction, could be an alternative to standard treatments, but its use in clinical practice is still limited. The potential benefit of combining radiotherapy with targeted therapies and immunotherapy has yet to be explored in this lesion setting. This review explores the role of radiotherapy in the treatment of cutaneous and subcutaneous lesions, its impact on outcomes, and its association with other treatment modalities.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616425PMC
http://dx.doi.org/10.3390/cancers13225859DOI Listing

Publication Analysis

Top Keywords

radiotherapy treatment
8
distant metastases
8
neutron capture
8
radiotherapy
5
subcutaneous
4
treatment subcutaneous
4
subcutaneous melanoma
4
melanoma malignant
4
malignant melanoma
4
melanoma frequently
4

Similar Publications

Radioresistance in rectal cancer: can nanoparticles turn the tide?

Mol Cancer

January 2025

i3S - Instituto de Investigação e Inovação em Saúde, Universidade Do Porto, Rua Alfredo Allen 208, Porto, 4200‑135, Portugal.

Rectal cancer accounts for over 35% of the worldwide colorectal cancer burden representing a distinctive subset of cancers from those arising in the colon. Colorectal cancers exhibit a continuum of traits that differ with their location in the large intestine. Due to anatomical and molecular differences, rectal cancer is treated differently from colon cancer, with neoadjuvant chemoradiotherapy playing a pivotal role in the control of the locally advanced disease.

View Article and Find Full Text PDF

Infiltration and subtype analysis of CD3 + CD20 + T cells in lung cancer.

BMC Cancer

January 2025

Basic Research Center, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Center, School of Medicine, Sichuan Cancer Hospital & Institute, University of Electronic Science and Technology of China, Chengdu, China.

Background: CD3 + CD20 + T cells (T cells) are a subset of lymphocytes in the human body that are associated with inflammation. They originate from T cells interacting with B cells, and their levels are abnormally elevated in individuals with immune disorders, as well as in some cancer patients. The interplay between tumor immunity and inflammation is intricate, yet the specific involvement of T cells in local tumor immunity remains uncertain, with limited research on their subtypes.

View Article and Find Full Text PDF

Despite advances in precision oncology, clinical decision-making still relies on limited variables and expert knowledge. To address this limitation, we combined multimodal real-world data and explainable artificial intelligence (xAI) to introduce AI-derived (AID) markers for clinical decision support. We used xAI to decode the outcome of 15,726 patients across 38 solid cancer entities based on 350 markers, including clinical records, image-derived body compositions, and mutational tumor profiles.

View Article and Find Full Text PDF

Photobiomodulation therapy as an additional method for the treatment of temporomandibular disorder patients- a narrative review.

Lasers Med Sci

January 2025

Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, WITS University, South Africa.

The photobiomodulation therapy (PBMT) is promising additional therapy in the treatment of temporomandibular disorder (TMD). In this regard, the purpose of this narrative review is to give a wide-ranging, objective, and judicious view of the current knowledge on PBMT as an additional TMD treatment modality, with summarised updated information. Although the results of most research studies report improvement of pain in TMD patients, some state that sustainability of absence of pain after PBMT of TMD is of concern.

View Article and Find Full Text PDF

Background: This study proposes a modified lymph node (LN) staging category (BALN) on the basis of the number of positive LNs before (prepN) and after (ypN) neoadjuvant chemoradiotherapy (nCRT) to improve prognostic stratification in esophageal squamous cell carcinoma (ESCC).

Patients And Methods: A total of 381 patients with ESCC who underwent nCRT at three medical centers were retrospectively enrolled. The ypN categories were scored according to the eighth edition of the American Joint Committee of Cancer (AJCC) staging manual.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!